Intraoperative Ir-192 implantation for early breast cancer. Techniques and results
Journal Article
·
· Cancer (Philadelphia); (USA)
DOI:https://doi.org/10.1002/1097-0142(19900701)66:1<1::AID-CNCR2820660102>3.0.CO;2-X·
OSTI ID:6717140
- Thomas Jefferson Univ. Hospital, Philadelphia, PA (USA)
Patients with early breast cancer (T1-2 N0-1) can be treated by lumpectomy and irradiation with a local control and survival equal to more radical surgery. Between 1982 and 1988, 323 patients with early breast cancer were treated, when possible, with Ir-192 implants at the time of lumpectomy to a local dose of 2000 cGy in 40-50 hours. Ten to 14 days later, the whole breast was treated to 4500 cGy at 180 per fraction in 5 weeks. The 6-year actuarial survival for stages I and II disease was 98% and 91%, respectively, and the recurrence-free survival was 96% and 98%, respectively. When these 323 patients were evaluated by T status, a local control of 97% was the same for T1 and T2 lesions. The cosmetic results were good to excellent in 95% of the patients. This approach has improved our ability to accurately place the boost dose in the breast.
- OSTI ID:
- 6717140
- Journal Information:
- Cancer (Philadelphia); (USA), Journal Name: Cancer (Philadelphia); (USA) Vol. 66:1; ISSN 0008-543X; ISSN CANCA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Breast conservation treatment with perioperative interstitial irradiation
Conservative management of operable breast cancer. Ten years experience at the Foundation Curie. [Gamma radiation]
Primary management of operable breast cancer by minimal surgery and radiotherapy
Journal Article
·
Thu Oct 01 00:00:00 EDT 1987
· Am. J. Clin. Oncol.; (United States)
·
OSTI ID:5840737
Conservative management of operable breast cancer. Ten years experience at the Foundation Curie. [Gamma radiation]
Conference
·
Sun Oct 01 00:00:00 EDT 1978
· Cancer; (United States)
·
OSTI ID:6801484
Primary management of operable breast cancer by minimal surgery and radiotherapy
Conference
·
Sun Oct 01 00:00:00 EDT 1978
· Cancer; (United States)
·
OSTI ID:6801464
Related Subjects
550600 -- Medicine
550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
62 RADIOLOGY AND NUCLEAR MEDICINE
ANIMALS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ELECTRON CAPTURE RADIOISOTOPES
FRACTIONATED IRRADIATION
GLANDS
HEAVY NUCLEI
IMPLANTS
INTERNAL CONVERSION RADIOISOTOPES
IRIDIUM 192
IRIDIUM ISOTOPES
IRRADIATION
ISOMERIC TRANSITION
ISOTOPES
MAMMALS
MAMMARY GLANDS
MAN
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ORGANS
PATIENTS
PRIMATES
RADIATION DOSES
RADIATION SOURCE IMPLANTS
RADIATION SOURCES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SURGERY
SURVIVAL CURVES
THERAPY
VERTEBRATES
550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
62 RADIOLOGY AND NUCLEAR MEDICINE
ANIMALS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ELECTRON CAPTURE RADIOISOTOPES
FRACTIONATED IRRADIATION
GLANDS
HEAVY NUCLEI
IMPLANTS
INTERNAL CONVERSION RADIOISOTOPES
IRIDIUM 192
IRIDIUM ISOTOPES
IRRADIATION
ISOMERIC TRANSITION
ISOTOPES
MAMMALS
MAMMARY GLANDS
MAN
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ORGANS
PATIENTS
PRIMATES
RADIATION DOSES
RADIATION SOURCE IMPLANTS
RADIATION SOURCES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SURGERY
SURVIVAL CURVES
THERAPY
VERTEBRATES